Participated · Series B · Aug 2026

InduPro uses a proprietary proximity-guided platform to map spatial organization of proteins on the cell surface and discover selective co-target pairs for therapeutic development. Its lead program, IDP-001, is a potential first-in-class proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA-E1). IDP-001 was designed to enhance tumor selectivity, target internalization, and antitumor efficacy while aiming to preserve tolerability, and the first patient has been dosed in its Phase 1 study. The Phase 1 trial is enrolling adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors to evaluate safety, pharmacokinetics and preliminary antitumor activity. Beyond ADCs, InduPro is developing bispecific antibodies including antibody-drug conjugates and T-cell engagers to build a pipeline of first- and best-in-class programs. The company operates out of Seattle and Cambridge, Mass., and is advancing both clinical and preclinical programs supported by venture and strategic pharma investors.

Participated · Series B · Jun 2026

COUR Pharma develops first-in-class antigen-specific immune tolerance therapies using a proprietary nanoparticle platform that encapsulates disease-relevant antigens to reprogram autoimmune responses. Its lead program, CNP-103, encapsulates four recombinant proteins and is designed to induce tolerance to antigens driving type 1 diabetes; it is currently in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT06783309) in recently diagnosed adolescents and adults. COUR says the proteins in CNP-103 are believed to cover over 95% of known T1D-driving antigens and aims to prevent further islet cell destruction and preserve insulin production. The company is pursuing partnerships to advance CNP-104 for primary biliary cholangitis and CNP-106 for myasthenia gravis. COUR recently raised $50 million in a Series B to support the clinical advancement of CNP-103, with participation from strategic and venture investors including Lumira Ventures, Roche Venture Fund, and Sanofi.

Participated · Equity · Mar 2026

DiappyMed builds a digital therapy designed to personalize insulin dose calculations for people with type 1 or type 2 diabetes treated with a basal/bolus regimen. The company presents its solution as the first French therapy numérique dedicated to individualized insulin dosing and says it works with professionals de santé and patients. DiappyMed announced a strategic partnership with Sanofi to enable broad deployment of the therapy across France. The company aims to secure reimbursement from Assurance Maladie by 2026 and frames the recent financing and partnership as steps toward that objective. In support of its rollout, DiappyMed raised €5 million in an amorçage round led by Ventech and AFI Ventures with participation from SOFILARO/CALEN and IRDI Capital Investissement, and cited additional institutional partners and supporters. No revenue, user metrics, founding year, or valuation were disclosed in the available articles.

Participated · Equity · Mar 2026

Earendil Labs applies AI across discovery, design, optimization, and development to generate and progress protein-based biologics programs. Its AI-native platform has produced more than 40 programs and includes HXN-1001, a half-life extended anti-TL1A antibody that the company says is ready for Phase 2 clinical development, with multiple IND submissions planned in 2026 and 2027. The company works through a combination of internal pipeline development and strategic partnerships, including a 2025 worldwide exclusive license agreement and broader strategic collaboration with Sanofi covering multiple programs. Earendil operates alongside affiliate Helixon Therapeutics and targets therapies for autoimmune diseases, cancer, and other areas of unmet medical need. With the announced $787 million financing, the company plans to scale its AI-driven R&D organization, expand scientific and engineering teams, and advance multiple internal programs toward clinical milestones.

Participated · Series B · Feb 2026

Altesa BioSciences is focused on treating chronic lung diseases by targeting the viral infections that trigger respiratory exacerbations. Its lead oral candidate, vapendavir, is designed to neutralise rhinovirus—the predominant cause of exacerbations in millions of COPD and asthma patients. In a recently completed Challenge Study, vapendavir improved upper and lower airway symptoms, shortened illness duration, lowered inflammatory markers, and preserved small-airway function relative to placebo. The company projects that, if approved, vapendavir could prevent up to 50 % of COPD exacerbations, improving quality of life and reducing healthcare costs. Altesa plans to launch the 900-patient Phase 2b CARDINAL study in the US and UK in Q2 2026 to further evaluate safety and efficacy. Led by former U.S. Assistant Secretary of Health Brett P. Giroir, M.D., and guided by a board chaired by Moncef Slaoui, Ph.D., the team includes seasoned executives with backgrounds at GSK and other major firms. The firm is headquartered in Atlanta and advocates for expanded access to modern respiratory diagnostics and therapeutics in underserved communities.